Strong epistatic interactions within a single protein

Molecular Biology and Evolution

Volumn 31, Issue 6, 2014, Pages 1546-1553

  Parera, Mariona ^a   Martinez, Miguel Angel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

epistasis; fitness; protein evolution

Indexed keywords

NONSTRUCTURAL PROTEIN 3; PROTEIN VARIANT; PROTEINASE; DANOPREVIR; ENZYME INHIBITOR; LACTAM; NS3 PROTEIN, HEPATITIS C VIRUS; SULFONAMIDE; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; ENZYME MECHANISM; EPISTASIS; GENETIC VARIABILITY; HEPATITIS C VIRUS; MOLECULAR EVOLUTION; NONHUMAN; PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; WILD TYPE; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; HEPACIVIRUS; METABOLISM; MUTATION RATE; PHYLOGENY;

AMINO ACID SUBSTITUTION; CATALYTIC DOMAIN; ENZYME INHIBITORS; EPISTASIS, GENETIC; EVOLUTION, MOLECULAR; HEPACIVIRUS; LACTAMS; MUTAGENESIS, SITE-DIRECTED; MUTATION RATE; PHYLOGENY; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84901446276     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/msu113     Document Type: Article

References (48)

1. Aita T, Husimi Y. 1996. Fitness spectrum among random mutants on Mt. Fuji-type fitness landscape. J Theor Biol. 182(4):469-485.
2. Aparicio E, Franco S, Parera M, Andres C, Tural C, Clotet B, Martinez MA. 2011. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients. J Virol. 85(12):5961-5969.
3. Bandelt HJ, Forster P, Rohl A. 1999. Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol. 16(1):37-48.
4. Bloom JD, Arnold FH, Wilke CO. 2007. Breaking proteins with mutations: threads and thresholds in evolution. Mol Syst Biol. 3:76.
5. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ. 2004. Evidence for positive epistasis in HIV-1. Science 306(5701):1547-1550.
6. Breen MS, Kemena C, Vlasov PK, Notredame C, Kondrashov FA. 2012. Epistasis as the primary factor in molecular evolution. Nature 490(7421):535-538.
7. Bridgham JT, Ortlund EA, Thornton JW. 2009. An epistatic ratchet constrains the direction of glucocorticoid receptor evolution. Nature 461(7263):515-519.
8. Brown KM, Costanzo MS, Xu W, Roy S, Lozovsky ER, Hartl DL. 2010. Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. Mol Biol Evol. 27(12):2682-2690.
9. Cabanillas L, Arribas M, Lazaro E. 2013. Evolution at increased error rate leads to the coexistence of multiple adaptive pathways in an RNA virus. BMC Evol Biol. 13:11.
10. da Silva J, Coetzer M, Nedellec R, Pastore C, Mosier DE. 2010. Fitness epistasis and constraints on adaptation in a human immunodeficiency virus type 1 protein region. Genetics 185(1):293-303.
11. de Visser JA, Cooper TF, Elena SF. 2011. The causes of epistasis. Proc Biol Sci. 278(1725):3617-3624.
12. Dean AM, Thornton JW. 2007. Mechanistic approaches to the study of evolution: the functional synthesis. Nat Rev Genet. 8(9):675-688.
13. Elena SF, Carrasco P, Daros JA, Sanjuan R. 2006. Mechanisms of genetic robustness in RNA viruses. EMBO Rep. 7(2):168-173.
14. Elena SF, Sole RV, Sardanyes J. 2010. Simple genomes, complex interactions: epistasis in RNA virus. Chaos 20(2):026106.
15. Franco S, Bellido R, Aparicio E, Canete N, Garcia-Retortillo M, Sola R, Tural C, Clotet B, Paredes R, Martinez MA. 2011. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors. J Viral Hepat. 18(10):e578-e582.
16. Franco S, Parera M, Aparicio E, Clotet B, Martinez MA. 2007. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology 45(4):899-910.
17. Gong LI, Suchard MA, Bloom JD. 2013. Stability-mediated epistasis constrains the evolution of an influenza protein. Elife 2:e00631.
18. Harms MJ, Thornton JW. 2013. Evolutionary biochemistry: revealing the historical and physical causes of protein properties. Nat Rev Genet. 14(8):559-571.
19. Hinkley T, Martins J, Chappey C, Haddad M, Stawiski E, Whitcomb JM, Petropoulos CJ, Bonhoeffer S. 2011. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet. 43(5):487-489.
20. Kouyos RD, Silander OK, Bonhoeffer S. 2007. Epistasis between deleterious mutations and the evolution of recombination. Trends Ecol Evol. 22(6):308-315.
21. Kryazhimskiy S, Dushoff J, Bazykin GA, Plotkin JB. 2011. Prevalence of epistasis in the evolution of influenza A surface proteins. PLoS Genet. 7(2):e1001301.
22. Kuiken C, Yusim K, Boykin L, Richardson R. 2005. The Los Alamos hepatitis C sequence database. Bioinformatics 21(3):379-384.
23. Lemon SM. 2010. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem. 285(30):22741-22747.
24. Liverton NJ, Holloway MK, McCauley JA, Rudd MT, Butcher JW, Carroll SS, DiMuzio J, Fandozzi C, Gilbert KF, Mao S, et al. 2008. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J Am Chem Soc. 130(14):4607-4609.
25. Lopez-Labrador FX, Moya A, Gonzalez-Candelas F. 2008. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther. 13(4):481-494.
26. Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, Neafsey DE, Weinreich DM, Hartl DL. 2009. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci USA. 106(29): 12025-12030.
27. Lunzer M, Miller SP, Felsheim R, Dean AM. 2005. The biochemical architecture of an ancient adaptive landscape. Science 310(5747):499-501.
28. Malcolm BA, Wilson KP, Matthews BW, Kirsch JF, Wilson AC. 1990. Ancestral lysozymes reconstructed, neutrality tested, and thermostability linked to hydrocarbon packing. Nature 345(6270):86-89.
29. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 66(5):3225-3229.
30. Mas A, Lopez-Galindez C, Cacho I, Gomez J, Martinez MA. 2010. Unfinished stories on viral quasispecies and Darwinian views of evolution. J Mol Biol. 397(4):865-877.
31. McCandlish DM, Rajon E, Shah P, Ding Y, Plotkin JB. 2013. The role of epistasis in protein evolution. Nature 497(7451):E1-E2; discussion E2-E3.
32. Merlo LM, Lunzer M, Dean AM. 2007. An empirical test of the concomitantly variable codon hypothesis. Proc Natl Acad Sci USA. 104(26):10938-10943.
33. Nevot M, Boesecke C, Parera M, Andrés C, Franco S, Revollo B, Ingiliz P, Tural C, Clotet B, Rockstroh JK, et al. 2014. Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients. J Viral Hepat. Advance Access published March 27, 2014, doi: 10.1111/jvh.12254.
34. O'Maille PE, Bakhtina M, Tsai MD. 2002. Structure-based combinatorial protein engineering (SCOPE). J Mol Biol. 321(4):677-691.
35. Ortlund EA, Bridgham JT, Redinbo MR, Thornton JW. 2007. Crystal structure of an ancient protein: evolution by conformational epistasis. Science 317(5844):1544-1548.
36. Parera M, Fernandez G, Clotet B, Martinez MA. 2007. HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol Biol Evol. 24(2):382-387.
37. Parera M, Martrus G, Franco S, Clotet B, Martinez MA. 2012. Canine hepacivirus NS3 serine protease can cleave the human adaptor proteins MAVS and TRIF. PLoS One 7(8):e42481.
38. Parera M, Perez-Alvarez N, Clotet B, Martinez MA. 2009. Epistasis among deleterious mutations in the HIV-1 protease. J Mol Biol. 392(2):243-250.
39. Pawlotsky JM. 2011. Treatment failure and resistance with directacting antiviral drugs against hepatitis C virus. Hepatology 53(5):1742-1751.
40. Poelwijk FJ, Kiviet DJ, Weinreich DM, Tans SJ. 2007. Empirical fitness landscapes reveal accessible evolutionary paths. Nature 445(7126):383-386.
41. Povolotskaya IS, Kondrashov FA. 2010. Sequence space and the ongoing expansion of the protein universe. Nature 465(7300):922-926.
42. Sanjuan R, Elena SF. 2006. Epistasis correlates to genomic complexity. Proc Natl Acad Sci USA. 103(39):14402-14405.
43. Schenk MF, Szendro IG, Salverda ML, Krug J, de Visser JA. 2013. Patterns of epistasis between beneficial mutations in an antibiotic resistance gene. Mol Biol Evol. 30(8):1779-1787.
44. Szendro IG, Schenk M, Franke J, Krug J, de Visser AGM. 2013. Quantitative analyses of empirical fitness landscapes. J Statist Mech. P01:005.
45. Wang K, Mittler JE, Samudrala R. 2006. Comment on "Evidence for positive epistasis in HIV-1". Science 312(5775):848; author reply 848.
46. Weinreich DM, Delaney NF, Depristo MA, Hartl DL. 2006. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312(5770):111-114.
47. Weinreich DM, Watson RA, Chao L. 2005. Perspective: sign epistasis and genetic constraint on evolutionary trajectories. Evolution 59(6):1165-1174.
48. Wellner A, Raitses Gurevich M, Tawfik DS. 2013. Mechanisms of protein sequence divergence and incompatibility. PLoS Genet. 9(7):e1003665.